Studies show that BCYRN1 is overexpressed in non-small-cell lung cancer [15–17], hepatocellular carcinoma [18–20], colorectal cancer [21–24], bladder cancer [25, 26], esophageal squamous cell carcinoma [27, 28], gastric cancer [29, 30], cervical cancer [31], ovarian cancer [32], and breast cancer [33] tissues compared to matched normal tissues. Here, BCYRN1 is linked to ovarian cancer.